Growth Metrics

Gyre Therapeutics (GYRE) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -58.11%
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -95.76%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -290.15%
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 59.59%
7 Evaxion A 62.56 Bn 62.54 Bn - -129.68%
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -10.08%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1,228.66%
10 Gyre Therapeutics 532.38 Mn 518.25 Mn 8.38 Mn -422.13%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -422.13%
Dec 31, 2025 -1,640.40%
Sep 30, 2025 221.17%
Jun 30, 2025 -87.47%
Mar 31, 2025 -64.18%
Dec 31, 2024 99.90%
Sep 30, 2024 -71.73%
Jun 30, 2024 90.39%
Mar 31, 2024 235.65%
Dec 31, 2023 -237.70%
Sep 30, 2023 181.41%
Jun 30, 2023 -96.41%
Mar 31, 2023 115.44%
Dec 31, 2022 -47.27%
Sep 30, 2022 80.65%
Jun 30, 2022 359.09%
Mar 31, 2022 35.22%
Dec 31, 2021 -7.42%
Sep 30, 2021 -57.41%
Jun 30, 2021 -15.54%
Mar 31, 2021 -453.61%
Dec 31, 2020 -38.92%
Sep 30, 2020 -26.18%
Jun 30, 2020 -25.17%
Mar 31, 2020 73.13%
Dec 31, 2019 -25.59%
Sep 30, 2019 -65.14%
Jun 30, 2019 -112.59%
Mar 31, 2019 -199.15%
Dec 31, 2018 -88.37%
Sep 30, 2018 -32.82%
Jun 30, 2018 34.05%
Mar 31, 2018 -21.85%
Dec 31, 2017 -53.41%
Sep 30, 2017 -21.42%
Jun 30, 2017 -103.35%
Mar 31, 2017 -15.20%
Dec 31, 2016 42.37%
Sep 30, 2016 -32.09%
Jun 30, 2016 -11.46%
Mar 31, 2016 46.80%
Dec 31, 2015 -42.82%
Sep 30, 2015 25.68%
Jun 30, 2015 46.71%
Mar 31, 2015 54.98%
Dec 31, 2014 65.90%
Sep 30, 2014 62.33%
Jun 30, 2014 34.23%
Mar 31, 2014 -85.95%
Dec 31, 2013 16.64%
Sep 30, 2013 -63.75%
Jun 30, 2013 -185.36%
Mar 31, 2013 -457.06%
Dec 31, 2012 -63.45%
Sep 30, 2012 12.98%
Jun 30, 2012 742.09%
Mar 31, 2012 -82.05%
Dec 31, 2011 -353.10%
Sep 30, 2011 -464.20%
Jun 30, 2011 -159.68%